Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsas y Mercados Espanoles  >  Almirall, S.A.    ALM   ES0157097017

ALMIRALL, S.A.

(ALM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Almirall S A : Pablo Alvarez appointed to President and GM of Almirall US

11/11/2020 | 03:31am EST
Pablo Alvarez appointed to President and GM of Almirall US 11 November 2020
  • Pablo will report directly to the CEO and serve on the Management Board effective immediately
  • He brings to this important role broad international pharmaceutical industry experience, including nearly 10 years in the US
  • Almirall US is poised for growth under strengthened leadership

Almirall, S.A. (ALM) the global biopharmaceutical company based in Barcelona, has announced that Pablo Alvarez has been promoted and will become the new President & GM of Almirall US, reporting directly to the CEO and serving on the Management Board effective immediately.

Pablo has previously served as Commercial Operations Director, overseeing several market companies such as the UK, Netherlands, Nordics, Belgium and France, as well as heading a number of global functions during which he gained extensive experience in medical dermatology.

Before joining Almirall, Pablo worked for McKinsey, GSK, BMS and AstraZeneca including key positions in Europe, LatAm and China and, importantly, nine years in the US. He has deep experience in launching products, implementing new business models, expanding to new geographies and strategy development. Pablo has a PhD in Pharmacy, with a focus on Microbiology from the Complutense University (Madrid, Spain), carried out a postdoctoral research at MIT (Boston, United States) and studied business and management at IESE Business School (Barcelona, Spain).

According to Peter Guenter, CEO of Almirall, 'Pablo will immediately add value with his extensive international commercial experience. His appointment is a clear opportunity to further strengthen Almirall's presence in the US market, drive the uptake of Seysara® (sarecycline) and ensure a successful launch of tirbanibulin, an innovative therapy for the management of Actinic Keratosis. Always with a clear focus on what is important for the business, he stands out for his great leadership, strategic thinking, analytical skills and ability to drive and manage change. We are proud of this internal promotion as it is an example of our commitment at Almirall towards our internal talent and the success of our talent review and succession planning process.'

Pablo stated, 'I am delighted to be leading a strong and experienced team, and to continue to build Almirall's presence and medical dermatology portfolio in the US. I am proud of the commitment to innovation and the patient centric approach that guides everything we do at Almirall, and I look forward to working with the team and the dermatology community in the US to bring further treatments that benefit those patients.'

We would like to thank Ron Menezes for his work and dedication to the company during the last 3 years. We wish him all the best in his future projects in his home state of California.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: 'Transform the patients' world by helping them realize their hopes and dreams for a healthy life'. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publically traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2019 were 908.4 million euros.

For more information, please visit almirall.com

Disclaimer

Almirall SA published this content on 11 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 November 2020 08:30:02 UTC


© Publicnow 2020
All news about ALMIRALL, S.A.
2020Athenex Secures FDA Approval for Klisyri in Treating Actinic Keratosis
MT
2020ALMIRALL S A : announces FDA approval of Klisyri® (tirbanibulin), a new innovati..
PU
2020ALMIRALL S A : has selected six digital health start-ups to join the second harv..
PU
2020ALMIRALL S A : Pablo Alvarez appointed to President and GM of Almirall US
PU
2020ALMIRALL S A : demonstrates resilient performance year to date despite COVID-19 ..
PU
2020ALMIRALL S A : The Board of Directors nominates Carlos Gallardo as Vice Presiden..
PU
2020ALMIRALL, S.A. : 3rd quarter results
CO
2020ALMIRALL S A : First complete dataset in the IL-23p19 class demonstrates ILUMETR..
PU
2020ALMIRALL S A : announces approval of the reimbursed price for Ilumetri®(tildraki..
PU
2020ALMIRALL S A : announces approval of the reimbursed pricefor Ilumetri®(tildrakiz..
PU
More news
Financials
Sales 2020 831 M 1 005 M 1 005 M
Net income 2020 87,2 M 105 M 105 M
Net Debt 2020 364 M 440 M 440 M
P/E ratio 2020 23,1x
Yield 2020 1,64%
Capitalization 2 064 M 2 497 M 2 497 M
EV / Sales 2020 2,92x
EV / Sales 2021 2,60x
Nbr of Employees 1 820
Free-Float 40,3%
Chart ALMIRALL, S.A.
Duration : Period :
Almirall, S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALMIRALL, S.A.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Average target price 15,49 €
Last Close Price 11,59 €
Spread / Highest target 59,6%
Spread / Average Target 33,6%
Spread / Lowest Target 3,54%
EPS Revisions
Managers and Directors
NameTitle
Michael McClellan Chief Executive & Financial Officer
Jorge Gallardo Ballart Chairman
Eloi Crespo Cervera Senior Vice President-Industrial Operations
Bhushan D. Hardas Chief Scientific Officer
Volker Koscielny Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALMIRALL, S.A.6.14%2 498
JOHNSON & JOHNSON6.67%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.-1.55%207 384
MERCK & CO., INC.-1.89%203 035